Overview
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Background
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/07/07 | Phase 2 | Completed | |||
2022/04/22 | Phase 1 | Active, not recruiting | |||
2022/04/08 | Phase 1 | Recruiting | |||
2021/06/24 | Phase 1 | Recruiting | |||
2021/06/11 | Phase 2 | Active, not recruiting | |||
2021/05/20 | Phase 2 | Active, not recruiting | |||
2020/11/12 | Phase 1 | Active, not recruiting | |||
2020/03/10 | Phase 1 | Active, not recruiting | |||
2019/11/15 | Phase 2 | Recruiting | |||
2019/11/15 | Phase 2 | Active, not recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||